Skip to Content

Seagen Inc Ordinary Shares SGEN

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Narrow-Moat Seagen Reports Solid Q2 Results Within Expectations; Maintaining Our $144 FVE

Rachel Elfman Equity Analyst

Analyst Note

| Rachel Elfman |

Narrow-moat Seagen reported solid second-quarter results in line with our expectations. Quarterly revenue was over $388 million, representing 40% growth year over year, thanks to continued strong performance from Adcetris, Padcev, and Tukysa. We are maintaining our $144 fair value estimate and narrow moat rating.

Read Full Analysis

Company Profile

Business Description

Seagen Inc. (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer and Tukysa for breast cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.

Contact
21823 - 30th Drive South East, Building 3
Bothell, WA, 98021
T +1 425 527-4000
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jun 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type Speculative Growth
Employees 2,092

Related